Floatz logo

Oxodotreotide

Gastroenteropancreatic Neuroendocrine Tumor

National Cancer Institute (NCI)protein_peptidePhase 4 / ApprovedActive
BBB
73/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
62/ 100
Competitive Position
89/ 100

Competitive context

33 Active assets in the Gastroenteropancreatic Neuroendocrine Tumor cohort.

Asset / SponsorPhaseRating
Octreotide Pamoate
Novartis Pharmaceuticals
Phase 3BB
Oxodotreotide
Vanderbilt-Ingram Cancer Center
Phase 4BB
EUDEMINE INJECTION
University of Maryland, Baltimore
Phase 4BB
Everolimus
RayzeBio, Inc.
Phase 3BB
DOTATOC
Jiangsu HengRui Medicine Co., Ltd.
Phase 3B

View all 46 →

Same molecule, other indications

Oxodotreotide is also rated in:

pancreatic neuroendocrine tumorDormant
BBB
Indicative ·
75 / 100
View asset →
digestive system neuroendocrine tumor, grade 1/2Dormant
BB
Indicative ·
69 / 100
View asset →
pancreatic neuroendocrine tumorDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →